Skip to content

Tag Archives: AML

How I treat acute myeloid leukemia in adults (strategies)


More than one quarter of a million adults throughout the world are diagnosed annually with acute myeloid leukemia (AML). Few diseases other than acute myeloid leukemia (AML) engender so much personal and institutional passion regarding treatment strategies. The median age of AML is 72 years of age, as reported by the Swedish Acute Leukemia Registry, a […]

Quizartinib: Surprising, Unprecedented Activity in Relapsed AML


ATLANTA, Georgia — The investigational agent quizartinib (Astellas/Ambit) has shown unprecedented activity in patients with relapsed and refractory acute myeloid leukemia (AML) in a phase 2 clinical trial. On the basis of these results, larger phase 3 clinical trials with the drug are being planned, according to Astellas/Ambit. Patients with AML can develop many different […]

Novel Approaches to the Treatment of Acute Myeloid Leukemia


Yesterday and today I read an literature by Gail J. Roboz in the Education Program Book by American Society of Hematology (ASH), which is named “Hematology” and published annually by the ASH in one volume per year. The name is “Novel Approaches to the Treatment of Acute Myeloid Leukemia”. In this article the author discussed several aspects […]